Somatropin (rhGH)Recombinant hormone medicine
Somatropin is recombinant human growth hormone. It has established medical uses in defined conditions, but those uses should not be extended to a general promise of youth, athletic recovery or better body composition.
What is Somatropin (rhGH)?
Somatropin is recombinant human growth hormone. It is used for defined growth-hormone deficiency and other product-specific growth conditions, rather than for short stature or ageing in general. 2
How it works
It supplies growth-hormone activity directly and stimulates downstream IGF-1 signalling. The consequences depend on age, diagnosis and whether a true deficiency is being replaced. 2
Effects studied
Growth and deficiency replacement
Paediatric assessment focuses on growth outcomes, while adult deficiency studies may assess body composition. These are not proof of improved athletic strength or longevity.
Evidence: Indication- and population-specific growth-hormone evidence. 2
What does the evidence show?
Condition- and product-specific endocrine evidence
A manufactured version of a human hormone
Somatropin reproduces human growth hormone, a protein involved in growth and metabolic regulation. Its effects include direct signalling and downstream activity involving IGF-1. Recombinant manufacturing provides a defined medicine, rather than relying on extracts of human tissue.
Replacement and other indications differ
Growth-hormone deficiency is one important use of somatropin. Certain products also have indications for other growth disorders, but these vary across brands and countries. An authorised use in one condition does not justify treatment of every cause of short stature or fatigue.
What an outcome should describe
In paediatric care, growth velocity and longer-term height are relevant but distinct measures. In adults with deficiency, the research questions differ. Changes in lean mass do not automatically mean improved strength, sporting performance or longer life, especially when the study population does not match the intended user.
The hormone has effects beyond growth
Fluid retention, joint symptoms and impaired glucose regulation are among the concerns. Active malignancy and certain acute critical illnesses are important contexts for restrictions, while children need monitoring matched to their diagnosis. Somatropin is a potent endocrine treatment for defined purposes. Its evidence does not make every growth-hormone fragment or secretagogue clinically equivalent.
Safety & status
Fluid retention, joint symptoms and glucose disturbances can occur. Active cancer and critical illness are among important product-related restrictions. 2
Country and product status
Country-specific product availability and authorisation require a separate current check.
Frequently asked questions
Does an adult body-composition change prove better strength?
No. Body composition and physical performance are separate outcomes.
Further reading
Sources
This entry was rewritten from our research archive. References below are reading leads unless a completed check is explicitly noted; a full independent evidence and regulatory review is still pending.
- Somatropin (rhGH) · retained archive reference Archive research lead · Retained archive reference; not independently checked for this draft
- Somatropin (rhGH) · retained archive reference Archive research lead · Retained archive reference; not independently checked for this draft
Research provenance
This name was discovered in the Superpower peptide index, archived 26 October 2026. Its ratings and reviewer attribution have not been adopted as our own. The archive informed this original editorial draft; independent source review is still pending.